DOCSLIB.ORG

Effects of Ketamine, MK-801, and Amphetamine on Regional Brain 2-Deoxyglucose Uptake in Freely Moving Mice Seiya Miyamoto, M.D., Ph.D., Jeremy N

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effects of Ketamine, MK-801, and Amphetamine on Regional Brain 2-Deoxyglucose Uptake in Freely Moving Mice Seiya Miyamoto, M.D., Ph.D., Jeremy N Effects of Ketamine, MK-801, and Amphetamine on Regional Brain 2-Deoxyglucose Uptake in Freely Moving Mice Seiya Miyamoto, M.D., Ph.D., Jeremy N. Leipzig, B.S., Jeffrey A. Lieberman, M.D., and Gary E. Duncan, Ph.D. Although the pathophysiology of schizophrenia remains cortical regions, hippocampal formation, nucleus unclear, behavioral effects in humans induced by N-methyl- accumbens, select thalamic nuclei, and basolateral D-aspartate (NMDA) antagonists, such as ketamine, amygdala. The behavior of mice given amphetamine was provide direction for formulating new pharmacologic similar to that of mice given MK-801. However, the brain models of the illness. The purpose of the present study was activity patterns induced by amphetamine were distinctly to clarify the roles of NMDA receptor antagonism, as well different from those observed after ketamine and MK-801 as dopamine-releasing properties of ketamine, in regional treatment. These results suggest that generalized behavioral brain metabolic activity and behavioral responses in mice. activation and increased dopamine release are insufficient to The effects of acute administration of ketamine (30 mg/kg, i.p.) account for the ketamine-induced alterations in regional were compared with those of the more selective non- brain metabolism, and that the effects of ketamine on 2-DG competitive NMDA antagonist MK-801 (0.3 and 0.5 mg/ uptake are likely related to a reduction in NMDA receptor kg, i.p.), and amphetamine (4 mg/kg, i.p.) on regional brain function. The data also suggest that ketamine-induced [14C]-2-deoxyglucose (2-DG) uptake, by using a high changes in 2-DG uptake may provide a useful paradigm for resolution autoradiographic technique in the freely moving translational research to better understand the mice. Both ketamine and MK-801 induced substantial and pathophysiology of schizophrenia. similar neuroanatomically selective alterations in regional [Neuropsychopharmacology 22: 400–412, 2000] 2-DG uptake. Remarkable increases in 2-DG uptake in © 2000 American College of Neuropsychopharmacology. response to the NMDA antagonists were seen in limbic Published by Elsevier Science Inc. KEY WORDS: Ketamine; Animal model; Schizophrenia; Although the etiology and pathophysiology of schizo- NMDA antagonist; Limbic cortex; Mice phrenia have not yet been elucidated, consistent clinical observations associated with a pharmacological chal- lenge with N-methyl-D-aspartate (NMDA) antagonists provide direction for formulating new pharmacological From the Department of Psychiatry, Pharmacology and UNC models of the illness. Since the late 1950s, phenylcycli- Mental Health and Neuroscience Clinical Research Center, School of Medicine (SM, JNL, JAL, GED), The University of North Carolina dine (PCP), a potent non-competitive NMDA antago- at Chapel Hill, Chapel Hill, NC 27599. nist, has been known to induce psychotic symptoms in Address correspondence to: Seiya Miyamoto, M.D., Ph.D. healthy humans that resemble some features of schizo- Department of Psychiatry, CB#7160 The University of North Caro- lina at Chapel Hill, Chapel Hill, NC 27599-7160, USA. Tel.: 919-966- phrenia (Luby et al. 1959; Davies and Beech 1960; Bak- 8237; Fax: 919-966-8994; E-mail: [email protected] ker and Amini 1961; Allen and Young 1978; Javitt and NEUROPSYCHOPHARMACOLOGY 2000–VOL. 22, NO. 4 © 2000 American College of Neuropsychopharmacology Published by Elsevier Science Inc. 0893-133X/00/$–see front matter 655 Avenue of the Americas, New York, NY 10010 PII S0893-133X(99)00127-X NEUROPSYCHOPHARMACOLOGY 2000–VOL. 22, NO. 4 NMDA Antagonist-induced Brain Metabolic Changes 401 Zukin 1991). Recently, it has been shown that subanes- 1991), monoaminergic systems (Ylitalo et al. 1976; Smith et thetic doses of ketamine, a non-competitive NMDA re- al. 1981; Irifune et al. 1991, 1997; Lindefors et al. 1997), and ceptor antagonist, can induce positive, negative, and cholinergic systems (Cohen et al. 1974; Scheller et al. 1996). cognitive schizophrenia-like symptoms in normal hu- The potency of ketamine at opiate, sigma, monoaminergic, mans (Krystal et al. 1994; Malhotra et al. 1996, 1997; and cholinergic receptors is considerably lower in com- Breier et al. 1997, 1998; Adler et al. 1998; Krystal et al. parison to NMDA antagonistic properties of the drug 1998; Newcomer et al. 1999). In chronic stabilized (Smith et al. 1980; Øye et al. 1991). However, exactly schizophrenic patients, subanesthetic doses of ketamine which molecular mechanisms mediate the effect of ket- can exacerbate cognitive impairment and induce posi- amine on behavior and regional brain metabolic activity tive psychotic symptoms that mimic the active episodes remains unclear. Thus, one purpose of the present study of their illness (Lahti et al. 1995a, 1995b; Malhotra et al. was to clarify the role of NMDA receptor antagonism in 1997). These clinical findings have led to the hypothesis ketamine-induced alterations in brain metabolic patterns that hypofunction of NMDA receptors in the central in mice, by comparing the effects of ketamine with the nervous system (CNS) is involved in the pathophysiol- more selective NMDA antagonist MK-801. ogy of schizophrenia (Deutsch et al. 1989; Olney 1989; NMDA antagonists, including ketamine and MK-801, Javitt and Zukin 1991; Ulas and Cotman 1993; Olney increase dopamine metabolism and release in several and Farber 1995; Coyle 1996; Jentsch and Roth 1999). brain regions in rodents (Doherty et al. 1980; Rao et al. The well-documented psychotomimetic effects of 1989; Wędzony et al. 1993; Hondo et al. 1994; Verma and NMDA antagonists in humans suggest that effects of the Moghaddam 1996; Irifune et al. 1997; Lindefors et al. drugs in experimental animals could represent useful 1997; Adams and Moghaddam 1998; Irifune et al. 1998). pharmacological models of schizophrenia. In our recent Activation of dopaminergic systems may participate in studies, striking effects of subanesthetic doses of ketamine certain behavioral effects induced by NMDA antago- were observed on regional patterns of 14C-2-deoxyglucose nists, since behavioral responses to NMDA receptor an- (2-DG) uptake in the rat brain (Duncan et al. 1998a, 1998b, tagonists are, at least in part, suppressed by dopamine 1999). Administration of subanesthetic doses of ketamine receptor antagonists in rats and mice (Corbett et al. to rats increased 2-DG uptake in neuroanatomically spe- 1995; Irifune et al. 1995; Lapin and Rogawski 1995; cific brain regions (Duncan et al. 1998a, 1999). Ketamine- Verma and Moghaddam 1996). To determine the in- induced metabolic activation was blocked by the atypical volvement of dopamine-releasing properties of keta- antipsychotic drug clozapine, but not by the typical anti- mine and MK-801 on regional 2-DG uptake, effects of psychotic haloperidol (Duncan et al. 1998b). Therefore, de- these drugs were compared to those of amphetamine, fining neurochemical mechanisms responsible for the which is well known to robustly induce dopamine re- brain metabolic effects induced by ketamine in laboratory lease (Snyder et al. 1972; Zetterstrom et al. 1983; Car- animals could suggest potential pathophysiological mech- boni et al. 1989; Kuczenski and Segal 1989). Comparison anisms in schizophrenia and pharmacotherapeutic actions of the effects of amphetamine with those of ketamine of atypical antipsychotic drugs. and MK-801 also allows assessment of the role of general- Studies of the effects of NMDA antagonists such as ized behavioral arousal and increased locomotor activity ketamine on brain 2-DG uptake have been limited to rats after 2-DG uptake induced by the NMDA antagonists. (Hawkins et al. 1979; Nelson et al. 1980; Crosby et al. 1982; Oguchi et al. 1982; Hammer and Herkenham 1983; Davis et al. 1988; Kurumaji et al. 1989; Duncan et al. 1998a, MATERIALS AND METHODS 1998b, 1999). The availability of transgenic mice deficient Animals in specific dopamine, serotonin, or NMDA receptor sub- units may present an opportunity to define neurochemical Twenty-six male ICR mice (Harlan Laboratories) weigh- mechanisms of ketamine-induced metabolic responses ing 37–49 g were used. The mice were housed under a 12 and effects of antipsychotic drugs in the 2-DG-ketamine h light-dark cycle with lights on at 0700 h and had contin- challenge model. For example, the paradigm of NMDA uous access to food and water. All animal use procedures antagonist-induced alterations in brain 2-DG uptake in were in strict accordance with the National Institute of transgenic mice could be a useful tool to explore the po- Health (NIH) Guide for the Care and Use of Laboratory tential involvement of individual neurotransmitter recep- Animals and were approved by the University of North tor subtypes in the mechanisms of action of antipsychotic Carolina Institutional Animal Care Committee. drugs, as well as ketamine itself. The goal of the present study was to characterize the neurobiological responses High Resolution Autoradiographic Analysis of to NMDA antagonist administration in mice. 14C-2-DG Uptake While ketamine has well-documented NMDA receptor antagonistic properties, the drug has a number of other The high-resolution autoradiographic procedures for pharmacological actions in the CNS. Ketamine acts on opi- analysis of [14C]-2-deoxyglucose (2-DG) uptake were ate receptors (Smith et al. 1980), sigma receptors (Øye et al. performed according to the method described previ- 402 S. Miyamoto et al. NEUROPSYCHOPHARMACOLOGY 2000–VOL. 22, NO. 4 ously (Duncan and Stumpf 1990, 1991; Duncan 1992) Happauge NY) and quantified using NIH Image Soft- with the following slight modifications. Mice were ware. The optical densities in autoradiograms were in transported from the animal quarters to the laboratory the linear range of the film as assessed in relation to 14C- and singly housed for 3 h before initiation of the 2-DG standards (Amersham Microscale). Data are expressed experiment. Mice exhibited minimal locomotor activity as ratios of optical density in gray matter regions rela- after this habituation period. Ketamine (30 mg/kg), tiveto that in the corpus callosum as previously de- MK-801 (0.3 or 0.5 mg/kg), amphetamine (4 mg/kg), or scribed (Duncan et al.
Load more

Recommended publications
  • Dextromethorphan Attenuates Sensorineural Hearing Loss in an Animal Model and Population-Based Cohort Study
    International Journal of Environmental Research and Public Health Article Dextromethorphan Attenuates Sensorineural Hearing Loss in an Animal Model and Population-Based Cohort Study Hsin-Chien Chen 1,* , Chih-Hung Wang 1,2 , Wu-Chien Chien 3,4 , Chi-Hsiang Chung 3,4, Cheng-Ping Shih 1, Yi-Chun Lin 1,2, I-Hsun Li 5,6, Yuan-Yung Lin 1,2 and Chao-Yin Kuo 1 1 Department of Otolaryngology-Head and Neck Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan; [email protected] (C.-H.W.); [email protected] (C.-P.S.); [email protected] (Y.-C.L.); [email protected] (Y.-Y.L.); [email protected] (C.-Y.K.) 2 Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan 3 School of Public Health, National Defense Medical Center, Taipei 114, Taiwan; [email protected] (W.-C.C.); [email protected] (C.-H.C.) 4 Department of Medical Research, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan 5 Department of Pharmacy Practice, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan; [email protected] 6 School of Pharmacy, National Defense Medical Center, Taipei 114, Taiwan * Correspondence: [email protected]; Tel.: +886-2-8792-7192; Fax: +886-2-8792-7193 Received: 31 July 2020; Accepted: 28 August 2020; Published: 31 August 2020 Abstract: The effect of dextromethorphan (DXM) use in sensorineural hearing loss (SNHL) has not been fully examined. We conducted an animal model and nationwide retrospective matched-cohort study to explore the association between DXM use and SNHL.
    [Show full text]
  • The Excitotoxin Quinolinic Acid Induces Tau Phosphorylation in Human Neurons
    The Excitotoxin Quinolinic Acid Induces Tau Phosphorylation in Human Neurons Abdur Rahman1,4., Kaka Ting2, Karen M. Cullen3, Nady Braidy4, Bruce J. Brew2,5, Gilles J. Guillemin2,4.* 1 Department of Family Sciences, College for Women, Kuwait University, Shuwaikh, Kuwait, 2 St Vincent’s Hospital, Centre for Applied Medical Research, Department of Neuroimmunology, Darlinghurst, New South Wales, Australia, 3 Disciplines of Anatomy and Histology, School of Medical Science, The University of Sydney, New South Wales, Australia, 4 Department of Pharmacology, University of New South Wales, School of Medical Science, Sydney, New South Wales, Australia, 5 Department of Neurology, St Vincent’s Hospital, Darlinghurst, New South Wales, Australia Abstract Some of the tryptophan catabolites produced through the kynurenine pathway (KP), and more particularly the excitotoxin quinolinic acid (QA), are likely to play a role in the pathogenesis of Alzheimer’s disease (AD). We have previously shown that the KP is over activated in AD brain and that QA accumulates in amyloid plaques and within dystrophic neurons. We hypothesized that QA in pathophysiological concentrations affects tau phosphorylation. Using immunohistochemistry, we found that QA is co-localized with hyperphosphorylated tau (HPT) within cortical neurons in AD brain. We then investigated in vitro the effects of QA at various pathophysiological concentrations on tau phosphorylation in primary cultures of human neurons. Using western blot, we found that QA treatment increased the phosphorylation of tau at serine 199/202, threonine 231 and serine 396/404 in a dose dependent manner. Increased accumulation of phosphorylated tau was also confirmed by immunocytochemistry. This increase in tau phosphorylation was paralleled by a substantial decrease in the total protein phosphatase activity.
    [Show full text]
  • A Guide to Glutamate Receptors
    A guide to glutamate receptors 1 Contents Glutamate receptors . 4 Ionotropic glutamate receptors . 4 - Structure ........................................................................................................... 4 - Function ............................................................................................................ 5 - AMPA receptors ................................................................................................. 6 - NMDA receptors ................................................................................................. 6 - Kainate receptors ............................................................................................... 6 Metabotropic glutamate receptors . 8 - Structure ........................................................................................................... 8 - Function ............................................................................................................ 9 - Group I: mGlu1 and mGlu5. .9 - Group II: mGlu2 and mGlu3 ................................................................................. 10 - Group III: mGlu4, mGlu6, mGlu7 and mGlu8 ............................................................ 10 Protocols and webinars . 11 - Protocols ......................................................................................................... 11 - Webinars ......................................................................................................... 12 References and further reading . 13 Excitatory synapse pathway
    [Show full text]
  • Glycine Activated Ion Channel Subunits Encoded by Ctenophore
    Glycine activated ion channel subunits encoded by PNAS PLUS ctenophore glutamate receptor genes Robert Albersteina, Richard Greya, Austin Zimmeta, David K. Simmonsb, and Mark L. Mayera,1 aLaboratory of Cellular and Molecular Neurophysiology, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892; and bThe Whitney Laboratory for Marine Bioscience, University of Florida, St. Augustine, FL 32080 Edited by Christopher Miller, Howard Hughes Medical Institute, Brandeis University, Waltham, MA, and approved September 2, 2015 (received for review July 13, 2015) Recent genome projects for ctenophores have revealed the subunits and glutamate to GluN2 subunits for activation of ion presence of numerous ionotropic glutamate receptors (iGluRs) in channel gating (12, 14–17), as well as depolarization to relieve + Mnemiopsis leidyi and Pleurobrachia bachei, among our earliest ion channel block by extracellular Mg2 (18, 19). The initial metazoan ancestors. Sequence alignments and phylogenetic analy- annotation of the M. leidyi genome identified 16 candidate iGluR sis show that these form a distinct clade from the well-characterized genes (4), whereas in the draft genome of P. bachei, 14 iGluRs AMPA, kainate, and NMDA iGluR subtypes found in vertebrates. were annotated as kainate-like receptors (5). In view of growing Although annotated as glutamate and kainate receptors, crystal interest in the molecular evolution of ion channels and receptors, structures of the ML032222a and PbiGluR3 ligand-binding domains and the pivotal role that ctenophores play in our current un- (LBDs) reveal endogenous glycine in the binding pocket, whereas derstanding of nervous system development (20), we initiated a ligand-binding assays show that glycine binds with nanomolar af- structural and functional characterization of glutamate receptors finity; biochemical assays and structural analysis establish that glu- expressed in both species.
    [Show full text]
  • Download Product Insert (PDF)
    Product Information Quinolinic Acid Item No. 14941 CAS Registry No.: 89-00-9 Formal Name: 2,3-pyridinedicarboxylic acid Synonyms: NSC 13127, NSC 18836, NSC 403247 O N MF: C7H5NO4 FW: HO 167.1 HO Purity: ≥98% Stability: ≥2 years at -20°C Supplied as: A crystalline solid O λ UV/Vis.: max: 216, 264 nm Laboratory Procedures For long term storage, we suggest that quinolinic acid be stored as supplied at -20°. It should be stable for at least two years. Quinolinic acid is supplied as a crystalline solid. A stock solution may be made by dissolving the quinolinic acid in the solvent of choice. Quinolinic acid is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of quinolinic acid in these solvents is approximately 16 mg/ml. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of quinolinic acid can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of quinolinic acid in PBS, pH 7.2, is approximately 0.5 mg/ml. We do not recommend storing the aqueous solution for more than one day. Quinolinic acid is an endogenous agonist at NMDA receptors that is generated through the metabolism of tryptophan in the kynurenine pathway.1 By overactivating NMDA receptors, quinolinic acid produces neurotoxicity, which has been implicated in certain neurodegenerative disorders.2 Quinolinic acid can also generate reactive oxygen species, has immunomodulatory actions, and promotes the formation of hyperphosphorylated tau proteins.3-5 References 1.
    [Show full text]
  • A Case Study on Addressing Abuse of a Safe and Effective Drug David C
    Spangler et al. Substance Abuse Treatment, Prevention, and Policy (2016) 11:22 DOI 10.1186/s13011-016-0067-0 DEBATE Open Access Dextromethorphan: a case study on addressing abuse of a safe and effective drug David C. Spangler1, Catherine M. Loyd1* and Emily E. Skor1,2 Abstract Background: Dextromethorphan is a safe, effective cough suppressant, available without a prescription in the United States since 1958. Due to a perceived prevalence of abuse of dextromethorphan by teens, in 2007 the Drug Enforcement Administration requested the Food and Drug Administration evaluate whether dextromethorphan should be recommended for scheduling under the Controlled Substances Act. The Food and Drug Administration held an Advisory Committee meeting in 2010 to provide a scientific and medical evaluation of dextromethorphan and its abuse potential. Discussion: To address reports of abuse, particularly by teens in the United States, the Consumer Healthcare Products Association initiated an abuse mitigation plan in 2010 with specific goals related to awareness of the behavior, perception of risk, social disapproval, and access to the products. In identifying abuse interventions, experts acknowledge that substance abuse among teens is a highly complex behavior and indicate that the best course of action is to address prevention by focusing on the factors that impact teen behavior. Conclusion: It is noteworthy that the annual prevalence of over-the-counter cough medicine abuse has sharply decreased since 2010. While a true cause-and-effect relationship cannot be assured, the Consumer Healthcare Products Association and its member companies believe that the increased awareness of the issue since the 2010 Food and Drug Administration Advisory Committee meeting, and the subsequent implementation of a well-delivered and targeted abuse mitigation plan that addressed the levers influencing teen decisions is contributing to the observed reduction in abuse.
    [Show full text]
  • Interplay Between Gating and Block of Ligand-Gated Ion Channels
    brain sciences Review Interplay between Gating and Block of Ligand-Gated Ion Channels Matthew B. Phillips 1,2, Aparna Nigam 1 and Jon W. Johnson 1,2,* 1 Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA; [email protected] (M.B.P.); [email protected] (A.N.) 2 Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA * Correspondence: [email protected]; Tel.: +1-(412)-624-4295 Received: 27 October 2020; Accepted: 26 November 2020; Published: 1 December 2020 Abstract: Drugs that inhibit ion channel function by binding in the channel and preventing current flow, known as channel blockers, can be used as powerful tools for analysis of channel properties. Channel blockers are used to probe both the sophisticated structure and basic biophysical properties of ion channels. Gating, the mechanism that controls the opening and closing of ion channels, can be profoundly influenced by channel blocking drugs. Channel block and gating are reciprocally connected; gating controls access of channel blockers to their binding sites, and channel-blocking drugs can have profound and diverse effects on the rates of gating transitions and on the stability of channel open and closed states. This review synthesizes knowledge of the inherent intertwining of block and gating of excitatory ligand-gated ion channels, with a focus on the utility of channel blockers as analytic probes of ionotropic glutamate receptor channel function. Keywords: ligand-gated ion channel; channel block; channel gating; nicotinic acetylcholine receptor; ionotropic glutamate receptor; AMPA receptor; kainate receptor; NMDA receptor 1. Introduction Neuronal information processing depends on the distribution and properties of the ion channels found in neuronal membranes.
    [Show full text]
  • Cellular Trafficking of Nicotinic Acetylcholine Receptors
    npg Acta Pharmacol Sin 2009 Jun; 30 (6): 656–662 Review Cellular trafficking of nicotinic acetylcholine receptors Paul A ST JOHN* Department of Cell Biology and Anatomy, University of Arizona College of Medicine, Tucson, AZ 85724, USA Nicotinic acetylcholine receptors (nAChRs) play critical roles throughout the body. Precise regulation of the cellular loca- tion and availability of nAChRs on neurons and target cells is critical to their proper function. Dynamic, post-translational regulation of nAChRs, particularly control of their movements among the different compartments of cells, is an important aspect of that regulation. A combination of new information and new techniques has the study of nAChR trafficking poised for new breakthroughs. Keywords: membrane traffic; protein traffic; biosynthesis; endocytosis; endoplasmic reticulum-associated degradation Acta Pharmacologica Sinica (2009) 30: 656–662; doi: 10.1038/aps.2009.76 Introduction ways, but two particular perturbations have been especially well studied and exert their effects at least in part by altering Nicotinic acetylcholine receptors (nAChRs) mediate the trafficking of nAChRs: 1) denervation changes the total synaptic transmission in the CNS, in autonomic ganglia, and number, the distribution, and the turnover rate of nAChRs in at neuromuscular junctions and other peripheral synapses. skeletal muscle; 2) prolonged exposure to nicotine increases The functional properties of these synapses differ, but in each the total number of nAChRs in neurons. Several of the stud- case, properly functional signaling requires cellular control ies reviewed here addressed the mechanisms by which these of the number, type, and location of nAChRs. Trafficking treatments alter nAChR trafficking. Other authors in this of nAChRs – the movement of nAChRs between compart- special issue will address other aspects of the effects of nico- ments of a cell, including the cell's biosynthetic and degrada- tine on nAChRs.
    [Show full text]
  • Linking Phencyclidine Intoxication to the Tryptophan-Kynurenine Pathway Therapeutic Implications for Schizophrenia
    Neurochemistry International 125 (2019) 1–6 Contents lists available at ScienceDirect Neurochemistry International journal homepage: www.elsevier.com/locate/neuint Linking phencyclidine intoxication to the tryptophan-kynurenine pathway: Therapeutic implications for schizophrenia T ∗ Hidetsugu Fujigakia, ,1, Akihiro Mourib,c,1, Yasuko Yamamotoa, Toshitaka Nabeshimac,d, Kuniaki Saitoa,c,d,e a Department of Disease Control and Prevention, Fujita Health University Graduate School of Health Sciences, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi 470- 1192, Japan b Department of Regulatory Science, Fujita Health University Graduate School of Health Sciences, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi 470-1192, Japan c Japanese Drug Organization of Appropriate Use and Research, 3-1509 Omoteyama, Tenpaku-ku, Nagoya, Aichi 468-0069, Japan d Advanced Diagnostic System Research Laboratory, Fujita Health University Graduate School of Health Sciences, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi 470-1192, Japan e Human Health Sciences, Graduate School of Medicine and Faculty of Medicine, Kyoto University, 54 Shogoinkawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan ARTICLE INFO ABSTRACT Keywords: Phencyclidine (PCP) is a dissociative anesthetic that induces psychotic symptoms and neurocognitive deficits in Phencyclidine rodents similar to those observed in schizophrenia patients. PCP administration in healthy human subjects in- Kynurenic acid duces schizophrenia-like symptoms such as positive and negative symptoms, and a range of cognitive deficits. It Quinolinic acid has been reported that PCP, ketamine, and related drugs such as N-methyl-D-aspartate-type (NMDA) glutamate Kynurenine pathway receptor antagonists, induce behavioral effects by blocking neurotransmission at NMDA receptors. Further, Schizophrenia NMDA receptor antagonists reproduce specific aspects of the symptoms of schizophrenia.
    [Show full text]
  • Kainate Receptors Depress Excitatory Synaptic Transmission at CA33CA1 Synapses in the Hippocampus Via a Direct Presynaptic Action
    The Journal of Neuroscience, May 1, 2001, 21(9):2958–2966 Kainate Receptors Depress Excitatory Synaptic Transmission at CA33CA1 Synapses in the Hippocampus via a Direct Presynaptic Action Matthew Frerking,1 Dietmar Schmitz,1 Qiang Zhou,1 Joshua Johansen,2 and Roger A. Nicoll1,2 Departments of 1Cellular and Molecular Pharmacology and 2Physiology, University of California, San Francisco, California 94143-0450 Kainate receptor activation depresses synaptic release of neu- excitation and subsequent release of a neuromodulator. Pre- rotransmitter at a number of synapses in the CNS. The mech- synaptic depolarization, achieved via increasing extracellular anism underlying this depression is controversial, and both K ϩ, caused a depression of the presynaptic fiber volley and an ionotropic and metabotropic mechanisms have been sug- increase in the frequency of miniature EPSCs. Neither effect gested. We report here that the AMPA/kainate receptor ago- was observed with DA, suggesting that DA does not depress nists domoate (DA) and kainate (KA) cause a presynaptic de- transmission via a presynaptic depolarization. However, the pression of glutamatergic transmission at CA33CA1 synapses effects of DA were abolished by the G-protein inhibitors in the hippocampus, which is not blocked by the AMPA recep- N-ethylmaleimide and pertussis toxin. These results suggest tor antagonist GYKI 53655 but is blocked by the AMPA/KA that KA receptor activation depresses synaptic transmission at receptor antagonist CNQX. Neither a blockade of interneuronal this synapse via a direct, presynaptic, metabotropic action. discharge nor antagonists of several neuromodulators affect Key words: domoate; kainate; metabotropic; presynaptic; the depression, suggesting that it is not the result of indirect hippocampus; CA1 Neurotransmitter receptors in the CNS can be separated into two use-dependent depression.
    [Show full text]
  • Lithium Stimulates Glutamate "Release" and Inositol 1,4,5
    Proc. Nat!. Acad. Sci. USA Vol. 91, pp. 8358-8362, August 1994 Neurobiology Lithium stimulates glutamate "release" and inositol 1,4,5-trisphosphate accumulation via activation of the N-methyl-D-aspartate receptor in monkey and mouse cerebral cortex slices (manic depression/bipolar disorder/primates) JOHN F. DIXON, GEORGYI V. Los, AND LOWELL E. HOKIN* Department of Pharmacology, University of Wisconsin Medical School, 1300 University Avenue, Madison, WI 53706 Communicated by Henry Lardy, May 9, 1994 (received for review February 18, 1994) ABSTRACT Beginning at therapeutic concentrations (1- showed lithium-stimulated increases in Ins(1,4,5)P3 and 1.5 mM), the anti-manic-depressive drug lithium stimulated inositol 1,3,4,5-tetrakisphosphate (2). the release of glutamate, a major excitatory neurotransmitter In the case of rhesus monkey, neither inositol nor an in the brain, in monkey cerebral cortex slices in a time- and agonist was required to demonstrate lithium-stimulated ac- concentration-dependent manner, and this was associated with cumulation of Ins(1,4,5)P3 (3). This suggested that an endog- increased inositol 1,4,5-trisphosphate [Ins(1,4,5)P3] accumu- enous neurotransmitter was involved in the lithium effect. lation. (±)-3-(2-Carboxypiperazin-4-yl)propyl-1-phosphoric We show here that, beginning at therapeutic concentrations, acid (CPP), dizocilpine (MK-801), ketamine, and Mg2+- lithium stimulated the release ofglutamate in rhesus monkey antagonists to the N-methyl-D-aspartate (NMDA) recep- and mouse cerebral cortex slices, and this in turn increased tor/channel complex selectively inhibited lithium-stimulated accumulation of Ins(1,4,5)P3 via activation of the N-methyl- Ins(t,4,5)P3 accumulation.
    [Show full text]
  • Systemic Approaches to Modifying Quinolinic Acid Striatal Lesions in Rats
    The Journal of Neuroscience, October 1988, B(10): 3901-3908 Systemic Approaches to Modifying Quinolinic Acid Striatal Lesions in Rats M. Flint Beal, Neil W. Kowall, Kenton J. Swartz, Robert J. Ferrante, and Joseph B. Martin Neurology Service, Massachusetts General Hospital, and Department of Neurology, Harvard Medical School, Boston, Massachusetts 02114 Quinolinic acid (QA) is an endogenous excitotoxin present mammalian brain, is an excitotoxin which producesaxon-spar- in mammalian brain that reproduces many of the histologic ing striatal lesions. We found that this compound produced a and neurochemical features of Huntington’s disease (HD). more exact model of HD than kainic acid, sincethe lesionswere In the present study we have examined the ability of a variety accompaniedby a relative sparingof somatostatin-neuropeptide of systemically administered compounds to modify striatal Y neurons (Beal et al., 1986a). QA neurotoxicity. Lesions were assessed by measurements If an excitotoxin is involved in the pathogenesisof HD, then of the intrinsic striatal neurotransmitters substance P, so- agentsthat modify excitotoxin lesionsin vivo could potentially matostatin, neuropeptide Y, and GABA. Histologic exami- be efficacious as therapeutic agents in HD. The best form of nation was performed with Nissl stains. The antioxidants therapy from a practical standpoint would be a drug that could ascorbic acid, beta-carotene, and alpha-tocopherol admin- be administered systemically, preferably by an oral route. In the istered S.C. for 3 d prior to striatal QA lesions had no sig- presentstudy we have therefore examined the ability of a variety nificant effect. Other drugs were administered i.p. l/2 hr prior of systemically administered drugs to modify QA striatal neu- to QA striatal lesions.
    [Show full text]